HCW Biologics is trading 6.5% down at $1.86 after announcing a $1.5 million private placement, which may be prompting after-hours reassessment following its sharp regular-session advance. - The shares closed September 24, 2026, at $1.99 after gaining 19.88% during regular trading. - The placement with an existing stockholder covers 903,614 units at $1.6599 each to fund clinical trials and corporate purposes.